Vaxart, Inc. – Press Releases

Search

Year

September 21, 2023

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET .

September 06, 2023

PDF Version

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection rate, a non-statistically significant reduction in norovirus acute gastroenteritis (AGE), and a

August 03, 2023

PDF Version

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and

July 27, 2023

PDF Version

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August

July 06, 2023

PDF Version

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Met all primary endpoints : Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge study in Q3 2023 SOUTH SAN FRANCISCO, Calif. , July 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced positive topline data from the

June 26, 2023

PDF Version

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

SOUTH SAN FRANCISCO, Calif. , June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that all four proposals were approved by Vaxart shareholders.

June 21, 2023

PDF Version

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

SOUTH SAN FRANCISCO, Calif. , June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023 , to vote on its proxy if they have not yet done so. The Company urges a y es vote on all Proxy proposals.

June 07, 2023

PDF Version

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000 , before deducting the underwriting discounts and

June 06, 2023

PDF Version

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition, Vaxart expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of

June 06, 2023

PDF Version

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif. , June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that the last subject has

Pagination

Current page 1
Page 2
Next page
Last page

Press Releases.

Search